Q3 2019 13F Holders as of 30 Sep 2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236M
-
Number of holders
-
138
-
Total 13F shares, excl. options
-
83.3M
-
Shares change
-
-1.55M
-
Total reported value, excl. options
-
$327M
-
Value change
-
-$6.48M
-
Put/Call ratio
-
0.05
-
Number of buys
-
59
-
Number of sells
-
-61
-
Price
-
$3.92
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q3 2019
172 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q3 2019.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 138 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 83.3M shares
of 236M outstanding shares and own 35.27% of the company stock.
Largest 10 shareholders include BAUPOST GROUP LLC/MA (24.5M shares), BlackRock Inc. (10.6M shares), Nantahala Capital Management, LLC (5.79M shares), ABRAMS CAPITAL MANAGEMENT, L.P. (5.66M shares), VANGUARD GROUP INC (5.47M shares), STATE STREET CORP (3.65M shares), Novo Holdings A/S (3.1M shares), Point72 Asset Management, L.P. (1.77M shares), Nuveen Asset Management, LLC (1.71M shares), and GEODE CAPITAL MANAGEMENT, LLC (1.58M shares).
This table shows the top 138 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.